
-
Trump talks up Canada deal chances with visiting PM
-
Knight rides her luck as England survive Bangladesh scare
-
Pro-Gaza protests flare in UK on anniversary of Hamas attack
-
Top rugby unions warn players against joining rebel R360 competition
-
Outcast Willis 'not overthinking' England absence despite Top 14 clean sweep
-
Trump says 'real chance' of Gaza peace deal
-
Macron urged to quit to end France political crisis
-
No.1 Scheffler seeks three-peat at World Challenge
-
Canadian PM visits Trump in bid to ease tariffs
-
Stocks falter, gold shines as traders weigh political turmoil
-
Senators accuse US attorney general of politicizing justice
-
LeBron's 'decision of all decisions' a PR stunt
-
Observing quantum weirdness in our world: Nobel physics explained
-
WTO hikes 2025 trade growth outlook but tariffs to bite in 2026
-
US Supreme Court hears challenge to 'conversion therapy' ban for minors
-
Italy's Gattuso expresses Gaza heartache ahead of World Cup qualifier with Israel
-
EU targets foreign steel to shield struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarterfinals
-
Stocks, gold rise as investors weigh AI boom, political turmoil
-
Swiatek coasts through Wuhan debut while heat wilts players
-
Denmark's Rune calls for heat rule at Shanghai Masters
-
Japanese football official sentenced for viewing child sexual abuse images
-
Stocks, gold steady amid political upheaval
-
'Veggie burgers' face grilling in EU parliament
-
Trio wins physics Nobel for quantum mechanical tunnelling
-
Two years after Hamas attack, Israelis mourn at Nova massacre site
-
German factory orders drop in new blow to Merz
-
Man City star Stones considered retiring after injury woes
-
Kane could extend Bayern stay as interest in Premier League cools
-
Renewables overtake coal but growth slows: reports
-
OpenAI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Extreme rains hit India's premier Darjeeling tea estates
-
Raducanu retires from opening match in Wuhan heat with dizziness
-
UK's Starmer condemns pro-Palestinian protests on Oct 7 anniversary
-
Tokyo stocks hit new record as markets extend global rally
-
Japan's Takaichi eyes expanding coalition, reports say
-
Canadian PM to visit White House to talk tariffs
-
Indonesia school collapse toll hits 67 as search ends
-
Dodgers hold off Phillies, Brewers on the brink
-
Lawrence sparks Jaguars over Chiefs in NFL thriller
-
EU channels Trump with tariffs to shield steel sector
-
Labuschagne out as Renshaw returns to Australia squad for India ODIs
-
Open AI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Tokyo stocks hit new record as Asian markets extend global rally
-
Computer advances and 'invisibility cloak' vie for physics Nobel
-
Nobel literature buzz tips Swiss postmodernist, Australians for prize
-
Dodgers hold off Phillies to win MLB playoff thriller
-
China exiles in Thailand lose hope, fearing Beijing's long reach
-
Israel marks October 7 anniversary as talks held to end Gaza war
-
Indians lead drop in US university visas
RYCEF | -1.03% | 15.54 | $ | |
AZN | 0.61% | 86.015 | $ | |
RELX | -2.02% | 45.49 | $ | |
GSK | 0.24% | 43.555 | $ | |
CMSC | -0.21% | 23.75 | $ | |
BTI | 1.42% | 51.915 | $ | |
NGG | 0.47% | 74.25 | $ | |
BP | -0.11% | 34.79 | $ | |
RIO | -0.64% | 66.555 | $ | |
RBGPF | 0% | 78.22 | $ | |
VOD | -0.27% | 11.26 | $ | |
SCS | -0.53% | 16.89 | $ | |
JRI | -0.35% | 14.13 | $ | |
BCC | 0.03% | 75.204 | $ | |
BCE | 0.43% | 23.29 | $ | |
CMSD | -0.25% | 24.38 | $ |

CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 8, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2025, after the stock market closes on Wednesday, August 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1727552&tp_key=38f7de0673. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, August 20, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13754956.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
F.Pedersen--AMWN